Table 1

Baseline demographic and disease characteristics

Canagliflozin
Placebo (n = 117)100 mg (n = 117)300 mg (n = 117)Total (N = 351)
Sex
 Male63 (53.8)69 (59.0)65 (55.6)197 (56.1)
 Female54 (46.2)48 (41.0)52 (44.4)154 (43.9)
Age, years42.0 ± 11.942.0 ± 11.642.8 ± 11.042.3 ± 11.5
Race*
 White106 (90.6)111 (94.9)102 (87.2)319 (90.9)
 Black/African American7 (6.0)5 (4.3)5 (4.3)17 (4.8)
 Asian2 (1.7)05 (4.3)7 (2.0)
 Other2 (1.7)1 (0.9)5 (4.3)8 (2.3)
HbA1c, %7.9 ± 0.67.9 ± 0.58.0 ± 0.57.9 ± 0.5
HbA1c, mmol/mol63 ± 6.663 ± 5.564 ± 5.563 ± 5.5
Body weight, kg83.0 ± 15.484.1 ± 14.282.9 ± 15.083.4 ± 14.8
BMI, kg/m228.0 ± 3.628.0 ± 3.928.1 ± 3.928.1 ± 3.8
eGFR, mL/min/1.73 m296.0 ± 14.897.4 ± 14.995.8 ± 16.596.4 ± 15.4
Duration of type 1 diabetes, years23.3 ± 11.022.0 ± 11.521.9 ± 10.622.4 ± 11.0
CSII use72 (61.5)74 (63.2)73 (62.4)219 (62.4)
MDI use45 (38.5)43 (36.8)44 (37.6)132 (37.6)
Prior severe hypoglycemia18 (15.4)15 (12.8)19 (16.2)52 (14.8)
Prior DKA14 (12.0)13 (11.1)15 (12.8)42 (12.0)
  • Data are mean ± SD or n (%).

  • *Percentages may not total 100.0 due to rounding.

  • †Includes multiple, other, and not reported.